|
rs3814113
|
|
|
0.820 |
GeneticVariation |
BEFREE |
To assess the potential implications of microRNAs in ovarian cancer, we investigated the associations between microRNA expression and seven ovarian cancer risk variants discovered from genome-wide association studies (GWAS), namely, rs3814113 on 9p22.2, rs2072590 on 2q31, rs2665390 on 3q25, rs10088218, rs1516982, rs10098821 on 8q24.21 and rs2363956 on 19p13.
|
22235027 |
2012 |
|
rs3814113
|
|
|
0.820 |
GeneticVariation |
BEFREE |
A genome-wide association study recently identified an association between the rare allele of the single-nucleotide polymorphism (SNP) rs3814113 (ie, the C allele) at 9p22.2 and decreased risk of ovarian cancer for women in the general population.
|
21169536 |
2011 |
|
rs113488022
|
|
|
0.750 |
GeneticVariation |
BEFREE |
In this study, we compared detection of the V600E mutation in serous ovarian tumors by VE1 immunostaining and by allele-specific polymerase chain reaction.
|
23089489 |
2013 |
|
rs113488022
|
|
|
0.750 |
GeneticVariation |
BEFREE |
The presence of the BRAF V600E mutation in SB/LGS ovarian cancer was associated with early stage disease and improved prognosis.
|
22930283 |
2013 |
|
rs113488022
|
|
|
0.750 |
GeneticVariation |
BEFREE |
No BRAF V600E mutations were detected in nonserous epithelial ovarian tumors.
|
22820660 |
2013 |
|
rs113488022
|
|
|
0.750 |
GeneticVariation |
BEFREE |
Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.
|
26490654 |
2015 |
|
rs113488022
|
|
|
0.750 |
GeneticVariation |
BEFREE |
One recurrent somatic mutation, p.V600E, is frequently found in several tumor types, such as melanoma, papillary thyroid carcinoma, colon cancer, and ovarian cancer.
|
20735442 |
2011 |
|
rs28897672
|
|
|
0.730 |
GeneticVariation |
BEFREE |
While the Cys61Gly mutation appeared underrepresented in ovarian cancer as compared with breast cancer cases from the same population (p = 0.01), the 4153delA mutation made a higher contribution to ovarian cancer than to breast cancer (p < 0.01).
|
20569256 |
2010 |
|
rs28897672
|
|
|
0.730 |
GeneticVariation |
BEFREE |
We identified a founder mutation (4153delA, 5382insC or C61G) in 6% of 235 unselected cases of breast cancer and in 19% of 43 unselected cases of ovarian cancer.
|
20345474 |
2010 |
|
rs28897672
|
|
|
0.730 |
GeneticVariation |
BEFREE |
The risk for breast cancer was 42% higher among first degree relatives of carriers of the C61G missense mutation compared to other mutations (HR = 1.42; p = 0.10) and the risk for ovarian cancer was lower than average (OR = 0.26; p = 0.03).
|
16227521 |
2006 |
|
rs11571833
|
|
|
0.720 |
GeneticVariation |
BEFREE |
The K3326X variant was associated with breast (ORw = 1.28, 95% CI = 1.17 to 1.40, P = 5.9x10(-) (6)) and invasive ovarian cancer</span> (ORw = 1.26, 95% CI = 1.10 to 1.43, P = 3.8x10(-3)).
|
26586665 |
2016 |
|
rs11571833
|
|
|
0.720 |
GeneticVariation |
BEFREE |
However, a stop-gain mutation, K3326* (rs11571833), confers risk of lung cancer and cancers of the upper-aero-digestive tract but only a modest risk of breast or ovarian cancer.
|
29767749 |
2018 |
|
rs2072590
|
|
|
0.720 |
GeneticVariation |
BEFREE |
The OC risk-associated SNP rs2072590 lies in non-coding DNA downstream of <i>HOXD3</i> and upstream of <i>HOXD1</i>, and it tags SNPs in the <i>HOXD3</i> 3' UTR.
|
29262571 |
2017 |
|
rs2072590
|
|
|
0.720 |
GeneticVariation |
BEFREE |
To assess the potential implications of microRNAs in ovarian cancer, we investigated the associations between microRNA expression and seven ovarian cancer risk variants discovered from genome-wide association studies (GWAS), namely, rs3814113 on 9p22.2, rs2072590 on 2q31, rs2665390 on 3q25, rs10088218, rs1516982, rs10098821 on 8q24.21 and rs2363956 on 19p13.
|
22235027 |
2012 |
|
rs10069690
|
|
|
0.710 |
GeneticVariation |
BEFREE |
A splicing variant in TERT, rs10069690, showed a statistically significant interaction with ET use for risk of serous ovarian cancer (p<sub>int</sub> = 0.013).
|
27420401 |
2016 |
|
rs10088218
|
|
|
0.710 |
GeneticVariation |
BEFREE |
To assess the potential implications of microRNAs in ovarian cancer, we investigated the associations between microRNA expression and seven ovarian cancer risk variants discovered from genome-wide association studies (GWAS), namely, rs3814113 on 9p22.2, rs2072590 on 2q31, rs2665390 on 3q25, rs10088218, rs1516982, rs10098821 on 8q24.21 and rs2363956 on 19p13.
|
22235027 |
2012 |
|
rs104886003
|
|
|
0.710 |
GeneticVariation |
BEFREE |
We also found that an activating (E545K) Pik3ca mutation, unlike Pten inactivation or Pik3ca H1047R mutation, cannot cooperate with Arid1a loss to promote ovarian cancer development in the mouse.
|
26279473 |
2016 |
|
rs11651755
|
|
|
0.710 |
GeneticVariation |
BEFREE |
As rs11651755 in HNF1B modified both the ovarian cancer risk and also the risk for endometriosis, HNF1B may be causally involved in the pathogenetic pathway leading from endometriosis to ovarian cancer.
|
28214017 |
2017 |
|
rs121913279
|
|
|
0.710 |
GeneticVariation |
BEFREE |
We also found that an activating (E545K) Pik3ca mutation, unlike Pten inactivation or Pik3ca H1047R mutation, cannot cooperate with Arid1a loss to promote ovarian cancer development in the mouse.
|
26279473 |
2016 |
|
rs121913343
|
|
|
0.710 |
GeneticVariation |
BEFREE |
We present the apparent BRCA1-related, although mutation negative, breast and ovarian cancer patient who subsequently was confirmed to be TP53 c.817C>T (p.R273C) mutation carrier and discuss the importance of peri-diagnostic oncogenetic TP53 testing in early breast cancer cases.
|
21535297 |
2011 |
|
rs121913529
|
|
|
0.710 |
GeneticVariation |
BEFREE |
In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer.
|
21632463 |
2011 |
|
rs2363956
|
|
|
0.710 |
GeneticVariation |
BEFREE |
To assess the potential implications of microRNAs in ovarian cancer, we investigated the associations between microRNA expression and seven ovarian cancer risk variants discovered from genome-wide association studies (GWAS), namely, rs3814113 on 9p22.2, rs2072590 on 2q31, rs2665390 on 3q25, rs10088218, rs1516982, rs10098821 on 8q24.21 and rs2363956 on 19p13.
|
22235027 |
2012 |
|
rs2665390
|
|
|
0.710 |
GeneticVariation |
BEFREE |
To assess the potential implications of microRNAs in ovarian cancer, we investigated the associations between microRNA expression and seven ovarian cancer risk variants discovered from genome-wide association studies (GWAS), namely, rs3814113 on 9p22.2, rs2072590 on 2q31, rs2665390 on 3q25, rs10088218, rs1516982, rs10098821 on 8q24.21 and rs2363956 on 19p13.
|
22235027 |
2012 |
|
rs397516436
|
|
|
0.710 |
GeneticVariation |
BEFREE |
High prevalence of codon 213Arg-->Stop mutations of the TP53 gene in human ovarian cancer in the southwestern part of The Netherlands.
|
9579562 |
1998 |
|
rs41293459
|
|
|
0.710 |
GeneticVariation |
BEFREE |
BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk.
|
22889855 |
2012 |